pharmaceutical investing BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
pharmaceutical investing BetterLife's Non-hallucinogenic LSD For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
pharmaceutical investing Promise of BetterLife's Non-hallucinogenic LSD For Treating Mood Disorders Highlighted in Medical Xpress Article
pharmaceutical investing BetterLife Files Amended and Restated Offering Document for Offering of Units
pharmaceutical investing Omineca Announces Upsized and Fully Allocated $2.8 Million Brokered Financing of Flow-Through Units
pharmaceutical investing Betterlife Publishes Promising Results from a Study Titled "A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders"
pharmaceutical investing BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 Accomplishments
pharmaceutical investing BetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology in Phoenix, Arizona
pharmaceutical investing BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives
